目的 探討采用復(fù)方紅豆杉膠囊與帕博利珠單抗聯(lián)合治療晚期非小細胞肺癌的臨床療效。方法 選取唐山中心醫(yī)院腫瘤科2022年10月—2024年12月收治的80例晚期非小細胞肺癌患者，按隨機數(shù)字表法分為對照組和治療組，每組40例。對照組iv帕博利珠單抗注射液，200 mg/次，每3周給藥1次。治療組在對照組的治療基礎(chǔ)上口服復(fù)方紅豆杉膠囊，2粒/次，每日3次，21 d為1個療程。兩組給藥2個療程觀察效果。觀察對比兩組療效情況，比較兩組生活質(zhì)量量表評分（FACT-L）、卡氏功能狀態(tài)量表評分（KPS）、細胞角蛋白19血清片段21-1（CYFRA21-1）、癌胚抗原（CEA）、鱗狀細胞癌抗原（SCC）、糖類抗原50（CA50）水平。結(jié)果 治療后，治療組的總有效率（92.50%）高于對照組（75.00%）（P＜0.05）。治療后，與對照組對比，治療組患者出現(xiàn)胸悶、咳嗽、胸痛、痰中帶血癥狀緩解時間均較短（P＜0.05）。治療后，兩組FACT-L評分、KPS評分較同組治療前顯著升高（P＜0.05）；治療后，與對照組對比，治療組患者FACT-L評分、KPS評分均更高（P＜0.05）。治療后，兩組CYFRA21-1、CEA、SCC、CA50水平較組內(nèi)治療前顯著降低；治療后，與對照組對比，治療組CYFRA21-1、CEA、SCC、CA50水平均較低（P＜0.05）。結(jié)論 復(fù)方紅豆杉膠囊與帕博利珠單抗協(xié)同治療晚期非小細胞肺癌效果顯著，對患者癥狀有較好的緩解作用，同時可以提高機體功能狀況，明顯改善患者生活質(zhì)量，降低患者腫瘤炎性反應(yīng)，值得借鑒與推廣。

Objective To investigate the efficacy of Compound Hongdoushan Capsules combined with pembrolizumab in treatment of advanced non-small cell lung cancer.Methods 80 Patients with advanced non-small cell lung cancer admitted to the Department of Oncology in Tangshan Central Hospital from October 2022 to December 2024 were selected and divided into control group and treatment group according to the random number tablet method, with 40 cases in each group. Patients in control group were iv Pembrolizumab Injection, 200 mg each time, once every 3 weeks. Patients in treatment group took Compound Hongdoushan Capsules orally on the basis of control group, 2 capsules each time, 3 times daily. 21 D constituted one course of treatment. The effects were observed after two courses of administration for two groups. The therapeutic effects of two groups were observed and compared, and the levels of FACT-L score, KPS score, CYFRA21-1, CEA, SCC, and CA50 in two groups were compared.Results After treatment, the total effective rate of treatment group (92.50%) was higher than that of control group (75.00%, P < 0.05). After treatment, compared with control group, the relief time of symptoms such as chest tightness, cough, chest pain and blood in sputum in treatment group was shorter (P < 0.05). After treatment, the FACT-L scores and KPS scores of two groups were significantly increased compared with those before treatment in the same group (P < 0.05). After treatment, compared with control group, the FACT-L score and KPS score of the patients in treatment group were higher (P < 0.05). After treatment, the levels of CYFRA21-1, CEA, SCC, and CA50 in both groups were significantly lower than those before treatment within the groups. After treatment, compared with control group, the levels of CYFRA21-1, CEA, SCC and CA50 in treatment group were all lower (P < 0.05).Conclusion The combined treatment of Compound Hongdoushan Capsules and pembrolizumab has a remarkable effect in advanced non-small cell lung cancer, and has a good alleviating effect on the symptoms of patients. At the same time, it can improve the functional status of the body, significantly improve the life quality of patients, and reduce the inflammatory response of tumors in patients,which is worthy of reference and promotion.

R979.1

河北省科技計劃項目（162777232）